The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
about
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyDual therapy strategies for COPD: the scientific rationale for LAMA + LABAA rational approach to single, dual and triple therapy in COPDPharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysisPositioning new pharmacotherapies for COPDDifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterolUmeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a reviewIntracellular interactions of umeclidinium and vilanterol in human airway smooth muscle.The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.Inhaled β-agonist does not modify sympathetic activity in patients with COPD.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDA repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjectsAclidinium bromide for the treatment of chronic obstructive pulmonary disease.Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm.Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a reviewNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic reviewVilanterol trifenatate for the treatment of COPD.Involvement of Ca2+ Signaling in the Synergistic Effects between Muscarinic Receptor Antagonists and β₂-Adrenoceptor Agonists in Airway Smooth Muscle.Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient ExperiencesPharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review
P2860
Q24561751-1605A57A-1EE6-43A7-955A-1C88E5E9F35CQ26752988-D2F558FA-1C06-4F96-9352-415B79A6240AQ26776477-75285576-A362-4F45-92A6-6FCAB07064FFQ26777927-B3CCC5E6-3FAC-4503-96DC-63AE69955F6BQ26778794-29F07720-DD04-413C-9EC2-57743718B83BQ26798659-DEA4E912-EB3E-49D0-AF43-3C1F7B3AD394Q26828602-D2A31BE1-6169-4B67-8CFC-FB98C2107774Q27015685-FD921D6F-0A97-4F2E-A5F7-7F776A4DC005Q33884409-8E9FF675-361C-4FD4-A870-C48AD5124976Q34644860-0DDF4F9E-4C8A-4720-B24A-D39325FF81C1Q35224900-0D2DAA75-016D-47FE-BFEA-883974D5DBCEQ35618080-0EA2D1A4-2DBF-4B33-98FE-CB946C584BFCQ37614090-28DF384A-AF17-417B-A496-A63D67762EF7Q37635200-8611C6F9-B0F2-44C2-BAC0-9839C1248AD2Q38066977-225F6A4F-DB2F-443F-908C-FEC369D0E547Q38118606-5154A121-7DA6-4E49-8FC7-A62735867100Q38148145-B8BC93FC-FC11-4860-8DB4-74DA3EFF37CEQ38154255-E6FF415E-1231-4C46-91A4-31344A57B9D1Q38218619-ED4FAD63-46D5-469C-8A6D-9CB3C4D2FAB9Q38235191-BB7B55BA-2580-41B5-8EDF-F39CCEA0BB9DQ38241442-DDCC395A-1DDA-480B-AF21-934D32021C19Q38266325-4D611859-D095-481E-B8CE-103DAC9635D4Q38284373-96A58916-52F3-43C2-B6B1-0797F06EA76FQ38322792-8D740C7D-0D75-4E67-9E38-749FC7954011Q38685216-CC672FA6-6832-4E01-804E-F00191B66AACQ38824916-ECEA287F-A848-40CF-822E-2C7DC78E6D7BQ39363086-261CE1D8-9A11-40B4-B6AC-DFFE7AAF0478Q42645176-2765238A-3C7C-4FC8-A1BD-31509C31F46BQ47966525-698D2979-C69E-4798-931E-6F4DE673A89FQ51671642-9C50FAFB-E364-4E1F-9580-F98A5FA1F204Q55335157-5772780F-D5D0-48FF-8096-5C5B75162ED4Q55360310-B8610B9A-D1E3-49B6-B8AA-F2D553E9FE6FQ58784324-1BD40713-E1EA-4240-8411-9A00A0A4338FQ58997823-FF30F518-2B79-4C8D-ADB0-5B04ABEA2631
P2860
The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
The efficacy and safety of the ...... ized placebo-controlled trial.
@ast
The efficacy and safety of the ...... ized placebo-controlled trial.
@en
The efficacy and safety of the ...... ized placebo-controlled trial.
@nl
type
label
The efficacy and safety of the ...... ized placebo-controlled trial.
@ast
The efficacy and safety of the ...... ized placebo-controlled trial.
@en
The efficacy and safety of the ...... ized placebo-controlled trial.
@nl
prefLabel
The efficacy and safety of the ...... ized placebo-controlled trial.
@ast
The efficacy and safety of the ...... ized placebo-controlled trial.
@en
The efficacy and safety of the ...... ized placebo-controlled trial.
@nl
P2093
P921
P356
P1433
P1476
The efficacy and safety of the ...... ized placebo-controlled trial.
@en
P2093
Brett Haumann
Courtney Crim
Frank Barnhart
Gregory Feldman
Jae-Jeong Shim
Lisa Sanford
Sally Lettis
Wolfgang Zachgo
P304
P356
10.1378/CHEST.11-2231
P407
P577
2012-07-01T00:00:00Z